ViiV Healthcare’s HIV drug Triumeq obtains Canadian approval

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK), Pfizer and Shionogi, has obtained approval in Canada, for its Triumeq (dolutegravir) 50mg, abacavir 600mg, and lamivudine 300mg) to treat patients with Human Immunodeficiency Virus (HIV-1) infection.

Triumeq is a once-daily single-pill regimen, which combines the integrase strand transfer inhibitor (INSTI) dolutegravir with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.

ViiV Healthcare Canada general manager Gregory Reinaud said: “Until we have a cure for HIV, we need new or different HIV medicines for patients. Everyone at ViiV is very proud that we can now offer Canadian physicians and patients living with HIV the first single-pill regimen containing dolutegravir.

“Today’s approval of Triumeq also demonstrates our continued commitment to developing and providing new treatment options.”

In September, ViiV Healthcare received marketing authorisation from the European Commission (EC) for Triumeq to treat HIV in adults and adolescents aged 12 years and older, and weighing, on average, 40kg.

The US Food and Drug Administration (FDA) approved Triumeq in August. Dolutegravir obtained US approval in August 2013, while Europe’s approval came in January under the brand name Tivicay.

Latest stories

Related stories

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Trump Executive Order to Cover 26 Drugs Critical to Health

US president Donald Trump has gone on to direct...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back